Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC is a research paper published in Journal of Thoracic Oncology (2023). On theSindex it has a DataRank of 0.494. It has been cited 26 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.494
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NIH
Grant: P30 CA016672
NCI NIH HHS
Grant: R01 CA240257
NCI NIH HHS
Grant: R01 CA234183
NCI NIH HHS
Grant: R50 CA265307
NCI NIH HHS
Grant: P50 CA070907
Damon Runyon Cancer Research Foundation
V Foundation for Cancer Research
University of Texas MD Anderson Cancer Center
FWCI
4.25
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals